Pyxis Oncology (PYXS) Non Operating Investment Income (2023 - 2025)
Pyxis Oncology's (PYXS) quarterly Non Operating Investment Income came in at -$16000.0 in Q4 2025, up 91.16% year-on-year from -$8369.9 in Q4 2024, and down 121.62% on a QoQ basis from $74000.0 in Q3 2025.
Pyxis Oncology (PYXS) Non Operating Investment Income (2023 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 3 years of Non Operating Investment Income data on file, last reported at -$16000.0 in Q4 2025.
- On a quarterly basis, Non Operating Investment Income rose 91.16% year-over-year to -$16000.0 in Q4 2025; TTM through Dec 2025 was -$117000.0, a 209.35% decrease from a year earlier, with the FY2025 full-year figure at -$117000.0, down 209.35% from the prior year.
- Non Operating Investment Income for Q4 2025 stood at -$16000.0, down from $74000.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for PYXS reached as high as $696000.0 in Q1 2023 and fell as low as -$781000.0 in Q2 2023.
- Historically, Non Operating Investment Income has averaged $4416.7 across 3 years, with a median of -$31000.0 in 2023.
- On a YoY basis, Non Operating Investment Income climbed as much as 2365.0% in 2024 and fell as far as 207.74% in 2024.
- Year by year, Non Operating Investment Income stood at $168000.0 in 2023, then plunged by 207.74% to -$181000.0 in 2024, then jumped by 91.16% to -$16000.0 in 2025.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$16000.0 in Q4 2025, $74000.0 in Q3 2025, and -$54000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Pyxis Oncology | 182.39 Mn | 115.53 Mn | 8.65 Mn | -16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Sep 30, 2024 | 453,000.00 |
| Sep 30, 2024 | 453,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Sep 30, 2023 | -20,000.00 |
| Sep 30, 2023 | -20,000.00 |